.jetcityimage/iStock Content through Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its top biopharma choice for 2025 and also ranked one more 9 titles in the space as over weight. The financial investment bank claimed in a note that it remains to strongly believe “diabesity is actually set to come to be.